Drug Trial Radar · NCT00134966
A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa
Last checked: Nov 19, 2026Latest source record: May 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
493
Actual
Start
Aug 2005
Primary completion
Sep 2007
Study completion Sep 2007
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 25, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to achieve approval for the use of carbidopa/levodopa/entacapone in early Parkinson's disease (PD) by demonstrating that when used as initial levodopa therapy in early PD, carbidopa/levodopa/entacapone provides significantly greater symptomatic benefit than immediate release carbidopa/levodopa administered at the same levodopa dosage level of 100 mg three times a day (t.i.d.).
Conditions
- Parkinson's Disease
Interventions
capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Symptom control change from baseline to week 39
Locations
60 sites in 8 countries. Site status is shown where the registry gives one.
Barrow Neurology Clinics at St. Joseph's Hosptial & Medical Center
Phoenix, Arizona
Coastal Neurological Medical Group, Inc
La Jolla, California
Neurosearch, Inc.
Reseda, California
University of Florida Health Science Center
Jacksonville, Florida
Mayo Clinic
Jacksonville, Florida
USF Medical Clinic
Tampa, Florida
Springfield Neurology Associates, LLC
Springfield, Massachusetts
Clinical Neuroscience Center
Southfield, Michigan
Melbourne Internal Medicine Associates
Westlake, Ohio
Westmoreland Neurology Associates, Inc.
Greensburg, Pennsylvania
Lankenau Hospital
Wynnewood, Pennsylvania
NeuroHealth
Warwick, Rhode Island
Coastal Neurology, PA
Beaufort, South Carolina
Senior Adults Specialty Research
Austin, Texas
Baylor College of Medicine, Parkinson's Disease Center
Houston, Texas
Neurology Associates
San Marcos, Texas
Blue Ridge Research Center at Roanoke Neurological Center
Roanoke, Virginia
Quebec Memory and Motor Skills Disorders Clinic
Québec, Canada
University of Saskatchewan, Royal University Hospital
Saskatoon, Canada
Heritage Medical Research Clinic
Calgary, Alberta, Canada
Site not named
Moncton, New Brunswick, Canada
Eastern Health Care - Health Sciences Centre, Neurology Department
HSC Room 5317, 300 Prince Philip Drive, Saint John's, Newfoundland and Labrador, Canada
Neurology Division, Health Science Center
Halifax, Nova Scotia, Canada
Cape Breton Regional Hospital, Neurology Department
Sydney, Nova Scotia, Canada
Grand River Hospital
Kitchener, Ontario, Canada
London Health Sciences Center, University Hospital, Rm. A10-026
London, Ontario, Canada
Centre for Movement Disorders
Markham, Ontario, Canada
Parkinson's & Neurodegenerative Disorders Clinic
Ottawa, Ontario, Canada
Ottawa Hospital, Civic Campus
Ottawa, Ontario, Canada
Hiren Desai Medicine Professional Corporation
Windsor, Ontario, Canada
Neuro Rive Sud
Greenfield Park, Quebec, Canada
Montreal General Hospital
Montreal, Quebec, Canada
Unite des Troubles du Mouvement Andre-Barbeau, CHUM-Hotel-Dieu
Montreal, Quebec, Canada
Centre de Recjerche Clinique du CHUS
Sherbrooke, Quebec, Canada
Dr. Felix Veloso Research
Regina, Saskatchewan, Canada
Neurologicka klinika
Katerinska 12, Praha 2, Czechia
FN-Nemocnice Pardubice
Kyjevska 44, Pardubice, Czechia
Neurologická klinika, Univerzita Palackého
I.P.Pavlova 6, Olomouc, Czechia
FN-neurologická klinika
Alej Svobody 80, Plzeň, Czechia
Dep. Of Neurology (Bitan 38, EEG institute)
Dep. of Neurology, Zerifin, Israel
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.